- Home
- TGTX vs RUSHB Comparison
TGTX vs RUSHB Comparison
Compare TGTX & RUSHB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- RUSHB
- Stock Information
- Founded
- TGTX 1993
- RUSHB 1965
- Country
- TGTX United States
- RUSHB United States
- Employees
- TGTX N/A
- RUSHB N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- RUSHB Retail-Auto Dealers and Gas Stations
- Sector
- TGTX Health Care
- RUSHB Consumer Discretionary
- Exchange
- TGTX Nasdaq
- RUSHB Nasdaq
- Market Cap
- TGTX 4.2B
- RUSHB 4.2B
- IPO Year
- TGTX 1995
- RUSHB 1996
- Fundamental
- Price
- TGTX $29.45
- RUSHB $59.22
- Analyst Decision
- TGTX Strong Buy
- RUSHB
- Analyst Count
- TGTX 4
- RUSHB 0
- Target Price
- TGTX $42.50
- RUSHB N/A
- AVG Volume (30 Days)
- TGTX 2.9M
- RUSHB 60.0K
- Earning Date
- TGTX 08-04-2025
- RUSHB 07-30-2025
- Dividend Yield
- TGTX N/A
- RUSHB 1.25%
- EPS Growth
- TGTX N/A
- RUSHB N/A
- EPS
- TGTX 0.36
- RUSHB 3.51
- Revenue
- TGTX $454,069,000.00
- RUSHB $7,687,256,000.00
- Revenue This Year
- TGTX $84.00
- RUSHB N/A
- Revenue Next Year
- TGTX $39.26
- RUSHB $9.87
- P/E Ratio
- TGTX $81.62
- RUSHB $15.25
- Revenue Growth
- TGTX 30.96
- RUSHB N/A
- 52 Week Low
- TGTX $21.11
- RUSHB $43.49
- 52 Week High
- TGTX $46.48
- RUSHB $61.55
- Technical
- Relative Strength Index (RSI)
- TGTX 42.03
- RUSHB 61.96
- Support Level
- TGTX $27.23
- RUSHB $53.79
- Resistance Level
- TGTX $28.85
- RUSHB $57.12
- Average True Range (ATR)
- TGTX 1.11
- RUSHB 1.84
- MACD
- TGTX 0.29
- RUSHB 0.15
- Stochastic Oscillator
- TGTX 99.05
- RUSHB 88.34
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About RUSHB Rush Enterprises Inc. Class B
Rush Enterprises Inc is a full-service, integrated retailer of commercial vehicles and related services. The company operates in a single segment; Truck Segment includes the operation of a network of commercial vehicle dealerships under the name Rush Truck Centers. It sells commercial vehicles manufactured by Peterbilt, International, Hino, Ford, Isuzu, IC Bus, and Blue Bird and also provides one-stop service for the needs of commercial vehicle customers, including retail sales of new and used commercial vehicles, aftermarket parts sales, service and repair facilities, financing, leasing and rental, and insurance products. The company's business is concentrated in the United States and Ontario, Canada commercial vehicle markets and related aftermarkets.